Medical Policy Updates

Notification of Policy Revisions Effective May 18, 2021 (Posted March 9, 2021)

Medical Policy Revision
Eptinezumab-jjmr (Vyepti™) “Notification” Updated initial authorization length to 6 months. Added the following criteria to initial and continuation sections of “When Covered” section: “If Vyepti 300 mg is requested, the patient has tried and had an inadequate response to the 100 mg strength.” Notification given 3/9/2021 for effective date 5/18/2021.